Brevan Howard Capital Management LP Invests $1 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Brevan Howard Capital Management LP purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 20,996 shares of the biopharmaceutical company's stock, valued at approximately $1,004,000.

A number of other hedge funds also recently made changes to their positions in HALO. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Shaker Investments LLC OH boosted its stake in shares of Halozyme Therapeutics by 12.3% in the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock valued at $3,601,000 after purchasing an additional 8,249 shares in the last quarter. Foster & Motley Inc. increased its position in shares of Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock worth $1,113,000 after purchasing an additional 12,630 shares in the last quarter. Jennison Associates LLC bought a new position in Halozyme Therapeutics during the 4th quarter valued at about $731,000. Finally, Koa Wealth Management LLC boosted its position in Halozyme Therapeutics by 10.6% in the fourth quarter. Koa Wealth Management LLC now owns 82,407 shares of the biopharmaceutical company's stock valued at $3,940,000 after buying an additional 7,924 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Stock Down 2.8 %

Shares of Halozyme Therapeutics stock traded down $1.87 on Friday, hitting $65.86. The company had a trading volume of 2,501,725 shares, compared to its average volume of 1,499,455. The stock has a 50-day moving average of $61.45 and a 200-day moving average of $55.83. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The firm has a market capitalization of $8.14 billion, a P/E ratio of 19.20, a P/E/G ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.13. The firm had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company's revenue for the quarter was up 35.2% on a year-over-year basis. During the same quarter last year, the business posted $0.79 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,697 shares of company stock worth $1,276,552. 2.90% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently commented on HALO. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $63.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.